Search

Your search keyword '"Masciale V."' showing total 2 results
Start Over Author "Masciale V." Publisher biomed central
2 results on '"Masciale V."'

1. Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes.

Author

Omarini C, Catani V, Mastrolia I, Toss A, Banchelli F, Isca C, Medici D, Ponzoni O, Brucale M, Valle F, Baschieri MC, D'Amico R, Masciale V, Chiavelli C, Caggia F, Bortolotti CA, Piacentini F, and Dominici M

Abstract

Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. However, limited knowledge exists on the levels and clinical meaning of miR-21 in extracellular vesicles (EVs) of patients with breast cancer (BC). We assessed EV-derived miR-21 levels in one hundred women: 30 with early BC (EBC), 30 with metastatic BC on treatment progression (MBC), 30 cancer survivors on follow-up (FU) and 10 healthy donors (HD) as age- and body mass index (BMI)-matched controls. EVs isolated from serum samples were characterized using nanoparticle tracking analysis, scanning electron microscopy and atomic force microscopy to detect their concentration, size, morphology and mechanical properties. The levels of miR-21 in EVs was evaluated using real time PCR and compared between groups (EBC, MBC and FU vs. HD) by calculating the fold change and ΔΔCt statistic. EVs size and concentration did not differ significantly among patient groups. In the EBC group, the clinical stage at diagnosis and tumor subtype did not influence miR-21 levels. The levels of miR-21 were higher in the MBC group than in the HD group (p = 0.029), mainly in those who were human epidermal growth factor receptor 2 (HER2)+ (p = 0.0005) and hormone receptor-positive (p = 0.036). In particular, in the HER2 + subgroup, the miR-21 levels were significantly higher in those with active BC (both EBC and MBC) than in HDs (p = 0.002). Our findings suggest that miR-21 may be a promising biomarker for diagnosis and tumor activity, mainly in HER2 + BC., Competing Interests: Declarations. Ethics approval and consent to participate: The data used in this manuscript were fully anonymized and made available for research following ethical approval from the AVEN (Area Vasta Emilia Nord) Ethics Committee (n. 1130/2020). Written informed consent was required for enrollment. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests., (© 2025. The Author(s).)

Published
2025
Full Text
View/download PDF

2. Metabolically activated and highly polyfunctional intratumoral VISTA + regulatory B cells are associated with tumor recurrence in early-stage NSCLC.

Author

Lo Tartaro D, Aramini B, Masciale V, Paschalidis N, Lofaro FD, Neroni A, Borella R, Santacroce E, Ciobanu AL, Samarelli AV, Boraldi F, Quaglino D, Dubini A, Gaudio M, Manzotti G, Reggiani F, Torricelli F, Ciarrocchi A, Neri A, Bertolini F, Dominici M, Filosso PL, Stella F, Gibellini L, De Biasi S, and Cossarizza A

Subjects
Humans, Lymphocytes, Tumor-Infiltrating metabolism, Lymphocytes, Tumor-Infiltrating immunology, Female, Male, Neoplasm Staging, Middle Aged, Cytokines metabolism, Aged, Biomarkers, Tumor metabolism, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung immunology, Lung Neoplasms metabolism, Lung Neoplasms pathology, Lung Neoplasms immunology, Lung Neoplasms genetics, Tumor Microenvironment immunology, B7 Antigens metabolism, B7 Antigens genetics, B-Lymphocytes, Regulatory metabolism, B-Lymphocytes, Regulatory immunology, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local metabolism
Abstract

B cells have emerged as central players in the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC). However, although there is clear evidence for their involvement in cancer immunity, scanty data exist on the characterization of B cell phenotypes, bioenergetic profiles and possible interactions with T cells in the context of NSCLC. In this study, using polychromatic flow cytometry, mass cytometry, and spatial transcriptomics we explored the intricate landscape of B cell phenotypes, bioenergetics, and their interaction with T cells in NSCLC. Our analysis revealed that TME contains diverse B cell clusters, including VISTA + Bregs, with distinct metabolic and functional profiles. Target liquid chromatography-tandem mass spectrometry confirmed the expression of VISTA on B cells. VISTA + Bregs displayed high metabolic demand and were able to produce different cytokines, including interleukin (IL)-10, transforming growth factor (TGF)-β, IL-6, tumor necrosis factor (TNF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Spatial analysis showed colocalization of B cells with CD4 + /CD8 + T lymphocytes in TME. The computational analysis of intercellular communications that links ligands to target genes, performed by NicheNet, predicted B-T interactions via VISTA-PSGL-1 axis. Colocalization analyses revealed that PSGL-1 T cells and VISTA + B cells are adjacent in the TME. Notably, tumor infiltrating CD8 + T cells expressing PSGL-1 exhibited enhanced metabolism and cytotoxicity. In NSCLC patients, prediction analysis performed by PENCIL revealed the presence of an association between PSGL-1 + CD8 + T cells and VISTA + Bregs with lung recurrence. Our findings suggest a potential interaction between Bregs and T cells through the VISTA-PSGL-1 axis, that could influence NSCLC recurrence., Competing Interests: Declarations. Ethics approval and consent to participate: The study protocol was approved by the local Ethical Committes (“Area Vasta Emilia Nord”, protocol number 0018007/21; “Comitato Etico della Romagna”, protocol number 7043/2021). All participants involved in this study provided written informed consent for both sample collection and data analyses. Detailed clinical information and the analysis methods employed for each sample are reported in Supplementary Table 1. Competing interests: All authors declare no competing interests., (© 2025. The Author(s).)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results